Brief: Sotio Exercises Option For Novel Antibody-Drug Conjugate Program Under Agreement With Legochem Biosciences
29/11/2022 13:13
Nov 29 (Reuters) - LegoChem Biosciences Inc 141080.KQ :
* SOTIO EXERCISES OPTION FOR NOVEL ANTIBODY-DRUG CONJUGATE
PROGRAM
UNDER AGREEMENT WITH LEGOCHEM BIOSCIENCES
Source text for Eikon: ID:nGNX52gXQs
Further company coverage: 141080.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on LigaChem Biosciences
See all newsBrief: Ligachem Biosciences To Issue 170 Billion Won Worth Of Convertible Bonds
Brief: Ligachem Biosciences - Issues 2.21 Million New Preferred Shares
Brief: Ligachem Biosciences To Divest 5 Billion Won Worth Of Own Shares
Brief: Ligachem Biosciences To Divest 17 Billion Won Worth Of Own Shares
Brief: Legochem Biosciences To Conduct Capital Increase Of 470 Billion Won For Operational Funds